Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: Improving the cost of pharmacotherapy

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 6, 2003, Pages 641-646

  Hassan, C ^a   De Francesco, V ^b   Zullo, A ^a   Scaccianoce, G ^c   Piglionica, D ^c   Ierardi, E ^b   Panella, C ^b   Morini, S ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b 'Riuniti' Hospital   (Italy)

^c Digestive Endoscopy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; RABEPRAZOLE; TINIDAZOLE; UREASE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DUODENUM ULCER; ERADICATION THERAPY; EVALUATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTACIDS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; TINIDAZOLE; TREATMENT OUTCOME;

EID: 0141650538     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01694.x     Document Type: Article

References (27)

1. De Francesco V, Zullo A, Rinaldi V, et al. Relationship between antral lymphocyte density and basal gastrin levels in patients with Helicobacter pylori infection. Digest Liver Dis 2000; 32: 676-81.
2. Vaira D, Gatta L, Ricci C, D'Anna L, Miglioli M. Helicobacter pylori: diseases, tests and treatment. Digest Liver Dis 2001; 33: 788-94.
3. McNamara D, O'Morain C, Helicobacter pylori and gastric cancer. Ital J Gastroenterol Hepatol 1998; 30(Suppl. 3): 294-8.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
5. Laheij RJ, Van Rossum LGM, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection. A meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-64.
6. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
7. Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5.
8. Fornè M, Viver JM, Esteve M, et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobater pylori infection and duodenal ulcer healing. Am J Gastroenterol 1998; 93: 35-8.
9. Sonnenberg A, Schwartz JS, Cutler AF, Vakil N, Bloom BS. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998; 158: 852-60.
10. Janssen MJR, Van Oijen AHAM, Verbeek ALM, Jansen JBMJ, de Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
11. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
12. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 383-8.
13. Calvet X, Ducons J, Guardial J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment Pharmacol Ther 2002; 16: 1261-7.
14. Lee JM, Breseling NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-96.
15. Deltenre M, Jonas C, Van Gossum M, Buser M, Otero J, De Koster E. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol 1997; 7(Suppl. 1): S39.44.
16. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14: 1237-43.
17. Hawkey CJ, Atherton JC, Treichel HC, Thuodlelfsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for eradication of Helicobacter pylori in patients with documented peptic disease. Aliment Pharmacol Ther 2003; 17: 1065-74.
18. Phull PS, Griffiths AE, Halliday D, Jacyna MR. One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. J Antimicrob Chemother 1995; 36: 1085-8.
19. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7.
20. Zullo A, Rinaldi V, Winn S. et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-8.
21. De Francesco V, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Digest Liver Dis 2001; 33: 676-9.
22. Focareta R, Forte G, Ciarleglio A, et al. Helicobacter pylori eradication: one week triple therapy vs. 10-day sequential regimen. Digest Liver Dis 2002; 34(Suppl. 1): A17(Abstract).
23. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-29.
24. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001; 13: 1281-4.
25. Spinzi GC, Bierti L, Bortoli A. et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 433-8.
26. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13: 1457-65.
27. Catalano F, Terminella C, Branciforte G, Bentivegna C, Brogna A, Scalia A. Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. Digestion 2002; 66: 154-9.